ExoLab Italia, a biotech startup specializing in plant-derived exosomes, has raised 5 million euros in Series A funding to support its industrial scale-up and international expansion.

Target Company Overview

ExoLab Italia is a biotech startup founded in 2020, specializing in the development of products and applications utilizing plant-derived exosomes. These cellular vesicles, extracted from fruit, are believed to enhance the efficacy of traditionally used ingredients across various industries, including cosmetics, pharmaceuticals, and nutraceuticals. ExoLab aims to leverage the abundant resources available in Italian organic agriculture to drive scientific discoveries. Through proprietary technology and a robust research and development program, ExoLab Italia has positioned itself as a leader in the innovation of natural functional active ingredients.

CeO Gabriele Campi emphasizes the strategic vision of the company, stating that the new capital of 5 million euros raised in a Series A funding round will enable ambitious plans for industrial scale-up, international expansion, and significant investments in human resources and local communities.

Industry Overview in Italy

The biotechnology sector in Italy is rapidly evolving, driven by advancements in medical research and increasing demand for innovative healthcare solutions. Italy is home to a robust agricultural sector, particularly in organic far